参考文献/References:
[1] Cousin C,Bracquart D,Contrepas A,et al. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma[J]. Hypertension,2009,53(6):1077-1082.
[2] Maruyama N,Segawa T,Kinoshita N,et al. Novel sandwich ELISA for detecting the human soluble (pro)renin receptor[J]. Front Biosci (Elite Ed),2013,5(2):583-590.
[3] Ichihara A,Yatabe MS. The (pro)renin receptor in health and disease[J]. Nat Rev Nephrol,2019,15(11):693-712.
[4] Lu X,Wang F,Xu C,et al. Soluble (pro)renin receptor via β-catenin enhances urine concentration capability as a target of liver X receptor[J]. Proc Natl Acad Sci U S A,2016,113(13):E1898-E1906.
[5] Wang F,Lu X,Liu M,et al. Renal medullary (pro)renin receptor contributes to angiotensin Ⅱ-induced hypertension in rats via activation of the local renin-angiotensin system[J]. BMC Med,2015,13:278.
[6] Advani A,Kelly DJ,Cox AJ,et al. The (Pro)renin receptor:site-specific and functional linkage to the vacuolar H+-ATPase in the kidney[J]. Hypertension,2009,54(2):261-269.
[7] 薛凯,周宝龙,方辉. 肾素(原)受体在肾脏炎症中的作用研究进展[J]. 医学综述,2022,28(5):865-870.
[8] Nakayama K. Furin:a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins[J]. Biochem J,1997,327(3):625-635.
[9] Seidah NG,Prat A. The biology and therapeutic targeting of the proprotein convertases[J]. Nat Rev Drug Discov,2012,11(5):367-383.
[10] Henrich S,Cameron A,Bourenkov GP,et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity[J]. Nat Struct Biol,2003,10(7):520-526.
[11] Hatsuzawa K,Nagahama M,Takahashi S,et al. Purification and characterization of furin,a Kex2-like processing endoprotease,produced in Chinese hamster ovary cells[J]. J Biol Chem,1992,267(23):16094-16099.
[12] Wei P,Zhao YG,Zhuang L,et al. Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta[J]. Biochem Biophys Res Commun,2001,280(3):744-755.
[13] 施文,李俊生. ADAM家族与肿瘤关系的研究现状[J]. 实用癌症杂志,2008,23(6):671-673.
[14] 蔡静莉,杨凌峰,王蓉. ADAM家族研究进展[J]. 国外医学(分子生物学分册),2000,22(4):197-201.
[15] Mochizuki S,Okada Y. ADAMs in cancer cell proliferation and progression[J]. Cancer Sci,2007,98(5):621-628.
[16] Hsia HE,Tüshaus J,Brummer T,et al. Functions of ’A disintegrin and metalloproteases (ADAMs)’ in the mammalian nervous system[J]. Cell Mol Life Sci,2019,76(16):3055-3081.
[17] Yoshikawa A,Aizaki Y,Kusano K,et al. The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space[J]. Hypertens Res,2011,34(5):599-605.
[18] Seidah NG,Sadr MS,Chrétien M,et al. The multifaceted proprotein convertases:their unique,redundant,complementary,and opposite functions[J]. J Biol Chem,2013,288(30):21473-21481.
[19] Marschner K,Kollmann K,Schweizer M,et al. A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism[J]. Science,2011,333(6038):87-90.
[20] Elagoz A,Benjannet S,Mammarbassi A,et al. Biosynthesis and cellular trafficking of the convertase SKI-1/S1P:ectodomain shedding requires SKI-1 activity[J]. J Biol Chem,2002,277(13):11265-11275.
[21] Ludwig J,Kerscher S,Brandt U,et al. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules[J]. J Biol Chem,1998,273(18):10939-10947.
[22] Nakagawa T,Suzuki-Nakagawa C,Watanabe A,et al. Site-1 protease is required for the generation of soluble (pro)renin receptor[J]. J Biochem,2017,161(4):369-379.
[23] Feng Y,Peng K,Luo R,et al. Site-1 protease-derived soluble (pro)renin receptor contributes to angiotensin Ⅱ-induced hypertension in mice[J]. Hypertension,2021,77(2):405-416.
[24] Xu C,Chen Y,Wang F,et al. Soluble (pro)renin receptor as a negative regulator of NCC (Na+-Cl- cotransporter) activity[J]. Hypertension,2021,78(4):1027-1038.
[25] Wang F,Xu C,Luo R,et al. Site-1 protease-derived soluble (pro)renin receptor targets vasopressin receptor 2 to enhance urine concentrating capability[J]. JCI Insight,2019,4(7):e124174.
[26] Fang H,Xu C,Lu A,et al. (Pro)renin receptor mediates albumin-induced cellular responses:role of site-1 protease-derived soluble (pro)renin receptor in renal epithelial cells[J]. Am J Physiol Cell Physiol,2017,313(6):C632-C643.
[27] Gonzalez AA,Lara LS,Luffman C,et al. Soluble form of the (pro)renin receptor is augmented in the collecting duct and urine of chronic angiotensin Ⅱ-dependent hypertensive rats[J]. Hypertension,2011,57(4):859-864.
[28] Prieto MC,Williams DE,Liu L,et al. Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension[J]. Am J Physiol Renal Physiol,2011,300(2):F581-F588.
[29] Ramkumar N,Stuart D,Peterson CS,et al. Loss of soluble (pro)renin receptor attenuates angiotensin-Ⅱ induced hypertension and renal injury[J]. Circ Res,2021,129(1):50-62.
[30] Fu Z,Wang F,Liu X,et al. Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin Ⅱ type 1 receptor[J]. Clin Sci (Lond) ,2021,135(6):793-810.
[31] Gatineau E,Gong MC,Yiannikouris F. Soluble prorenin receptor increases blood pressure in high fat-fed male mice[J]. Hypertension,2019,74(4):1014-1020.
[32] Gatineau E,Cohn DM,Poglitsch M,et al. Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system[J]. Am J Physiol Heart Circ Physiol,2019,316(3):H506-H515.
[33] Rahmouni K. Leptin-induced sympathetic nerve activation:signaling mechanisms and cardiovascular consequences in obesity[J]. Curr Hypertens Rev,2010,6(2):104-209.
[34] Obradovic D,Loncar G,Radenovic S,et al. Soluble (pro)renin receptor in elderly chronic heart failure patients[J]. Front Biosci (Landmark Ed),2020,25(10):1839-1853.
[35] Ikeda Y,Tsutsui K,Yamada Y,et al. Relationship between soluble (pro)renin receptor and renin activity in patients with severe heart failure[J]. J Clin Med,2020,9(12):4110.
[36] Gong L,Zhang S,Li L,et al. Elevated plasma soluble (pro)renin receptor levels are associated with left ventricular remodeling and renal function in chronic heart failure patients with reduced ejection fraction[J]. Peptides,2019,111:152-157.
[37] Amari Y,Morimoto S,Iida T,et al. Association between serum soluble (pro)renin receptor level and worsening of cardiac function in hemodialysis patients:a prospective observational study[J]. PLoS One ,2020,15(5):e0233312.
[38] Gafane-Matemane LF,Kruger R,Van Rooyen JM,et al. Soluble (pro)renin receptor is adversely associated with indices of left ventricular structure and function:The African-PREDICT Study[J]. J Cardiovasc Dev Dis,2022,9(5):130.
[39] Gladysheva IP,Sullivan RD,Ramanathan K,et al. Soluble (pro)renin receptor levels are regulated by plasma renin activity and correlated with edema in mice and humans with HFrEF[J]. Biomedicines,2022,10(8):1874.
[40] Magder S. The meaning of blood pressure[J]. Crit Care,2018,22(1):257.
[41] Wang F,Luo R,Peng K,et al. Soluble (pro)renin receptor regulation of ENaC involved in aldosterone signaling in cultured collecting duct cells[J]. Am J Physiol Renal Physiol,2020,318(3):F817-F825.W
[42] Fu Z,Zheng H,Kaewsaro K,et al. Mutagenesis of the cleavage site of (pro)renin receptor abrogates aldosterone-salt-induced hypertension and renal injury in mice[J]. Am J Physiol Renal Physiol,2023,324(1):F1-F11.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(8):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(8):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(8):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(8):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(8):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(8):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]